Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

Secretion of EGF-like domain of heregulinbeta promotes axonal growth and functional recovery of injured sciatic nerve.

Authors: Joung, I  Yoo, M  Woo, JH  Chang, CY  Heo, H  Kwon, YK 
Citation: Joung I, etal., Mol Cells. 2010 Nov;30(5):477-84. doi: 10.1007/s10059-010-0137-5. Epub 2010 Oct 14.
Pubmed: (View Article at PubMed) PMID:20957456
DOI: Full-text: DOI:10.1007/s10059-010-0137-5

Neuregulin 1 (NRG1) and epidermal growth factor receptor (ErbB) signaling pathways control Schwann cells during axonal regeneration in an injured peripheral nervous system. We investigated whether a persistent supply of recombinant NRG1 to the injury site could improve axonal growth and recovery of sensory and motor functions in rats during nerve regeneration. We generated a recombinant adenovirus expressing a secreted form of EGF-like domain from Heregulinbeta (sHRGbetaE-Ad). This virus, sHRGbetaE-Ad allowed for the secretion of 30-50 ng of small sHRGbetaE peptides per 10(7-8) virus particle outside cells and was able to phosphorylate ErbB receptors. Transduction of the concentrated sHRGbetaE-Ad into an axotomy model of sciatic nerve damage caused an effective promotion of nerve regeneration, as shown by histological features of the axons and Schwann cells, as well as increased expression of neurofilaments, GAP43 and S100 in the distal stump of the injury site. This result is consistent with longer axon lengths and thicker calibers observed in the sHRGbetaE-Ad treated animals. Furthermore, sensory and motor functions were significantly improved in sHRGbetaE-Ad treated animals when evaluated by a behavioral test. These results suggest a therapeutic potential for sHRGbetaE-Ad in treatment of peripheral nerve injury.


Disease Annotations
Gene Ontology Annotations
Objects Annotated

Additional Information

RGD Object Information
RGD ID: 10449012
Created: 2015-12-11
Species: All species
Last Modified: 2015-12-11
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.